πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,557 results for β€œplacebo” Clear

  1. SYNTOCINON 40 i.e./ml prΕ‘ilo za nos, raztopina, Oxytocin Placebo

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial

  2. Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo

    Disc Medicine

    Sjogren's disease

    phase 2 small molecule active

    1 trial

  3. Saxenda 6 mg/mL solution for injection in pre-filled pen, Saxenda 6 mg/mL solution for injection in pre-filled pen, Placebo for PF-07976016, Saxenda 6 mg/mL solution for injection in pre-filled pen

    Pfizer Australia Pty Ltd

    Obesity, Overweight

    phase 2 small molecule active

    1 trial

  4. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Beijing Research Institute

    Treatment of SjΓΆgren’s disease

    phase 2 small molecule active

    1 trial

  5. TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  6. TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  7. TAK-954 Placebo

    Takeda

    Postoperative Gastrointestinal Dysfunction

    phase 2 small molecule completed

    1 trial

  8. TEV-48574, Placebo IMP for sc infusion is provided as a liquid solution in the same formulation as TEV-48574, except for the absence of active protein.

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  9. TEV-53408, Placebo to match TEV-53408

    Lacuna Pharma Pty Ltd

    Celiac Disease

    phase 2 small molecule active

    1 trial

  10. TIN816, Placebo to TIN816 70mg powder for solution for injection or infusion

    Novartis Pharmaceuticals

    Acute kidney injury

    phase 2 small molecule active

    1 trial

  11. TIN816, Sterile 0.9% sodium chloride solution for infusion will be administered as placebo to participants randomized to the placebo treatment. The solution is ready to use in a 100mL infusion bag of 0.9% sodium chloride solution

    Novartis Pharmaceuticals

    Sepsis associated acute kidney injury

    phase 2 small molecule active

    1 trial

  12. TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, IOHEXOL , TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  13. TL-895, TL-895, TL-895, TL-895 matching placebo, TL-895, TL-895

    Lacuna Pharma Pty Ltd

    Indolent Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  14. TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 ΞΌg, 160 ΞΌg, or 320 ΞΌg), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  15. Tablets are oval, biconvex, plain and white to off white, Placebo for GSK4011499 Tablets are tablets for oral administration. Tablets are oval, biconvex, plain, and white to off white.

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  16. Tarperprumig Placebo, Tarperprumig

    Alexion Europe SAS

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

    phase 2 small molecule active

    1 trial

  17. The Placebo composition is the same of the IMP except the active ingredient

    Fondazione Telethon ETS

    Optic Pathway Glioma (OPG)

    phase 2 small molecule active

    1 trial

  18. The corresponding placebo solution consists of the 25 nM phosphate buffer solution with 4 ΞΌg of vitamin B2 added for colouring purposes only., RBD1016, Vemlidy 25 mg film-coated tablets.

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial

  19. The min-102 placebo is supplied as an oral suspension with similar appearance to min-102 drug product. min-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose

    Minoryx Therapeutics S.L.

    Rett Syndrome

    phase 2 small molecule active

    1 trial

  20. The placebo for the pantoprazole sodium 40 mg, 20 mg, 10 mg and 5 mg delayed release granules in HPMC capsules, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE

    Pfizer Australia Pty Ltd

    EROSIVE ESOPHAGITIS

    phase 2 small molecule active

    1 trial

  21. The placebo is commercially available 5% dextrose solution intended for IV, DYNE-251, DYNE-251

    Dyne Therapeutics

    Duchenne muscular dystrophy

    phase 2 small molecule active

    1 trial

  22. The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial

  23. The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP., BRENSOCATIB, BRENSOCATIB

    Insmed Limited

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  24. The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources